Psychedelic Archives

Debra BorchardtJune 8, 2023

No word on the release of fourth quarter earnings.

Debra BorchardtJune 6, 2023

Freedom to Operate had argued against the definition used by the PTAB in the decision.

Debra BorchardtMay 31, 2023

Compass Pathways plc (Nasdaq: CMPS) announced that Co-founder and Chief Innovation Officer Dr. Ekaterina Malievskaia will step down from her executive role effective June 16, 2023. She will remain a member of the Compass Pathways Board of Directors, while her executive responsibilities will be carried forward by the existing executive team. Dr. Ekaterina Malievskaia said, […]

Debra BorchardtMay 16, 2023

CEO: "2023 is the most important year in Seelos' history thus far."

Debra BorchardtMay 16, 2023

Filament is actively pursuing partnerships for development and testing of its compounds.

Debra BorchardtMay 11, 2023

Psychedelic drug company Compass Pathways plc (Nasdaq: CMPS) reported its financial results for the first quarter of 2023 and gave an update on recent progress across its business. Compass Pathways has no revenue at this time to report. It had a net loss of $24.2 million, or $0.57 loss per share (including non-cash share-based compensation […]

Debra BorchardtMay 2, 2023

CPT codes are essential when seeking reimbursement from insurance companies.

Debra BorchardtApril 20, 2023

Oregon Health Authority (OHA) released a statement on April 18 noting that the authority had licensed the state’s first three facilitators for providing psilocybin services. The licensing follows a regulatory framework created by M109, the Oregon Psilocybin Services Act. The OHA said it issued the licenses to David Naftalin, Alexander Polvi and Jeanette Small. “We […]

Debra BorchardtApril 13, 2023